Bristol-Myers Squibb Company (BMY)

74.81
NYSE : Health Care
Prev Close 74.66
Day Low/High 74.22 / 75.16
52 Wk Low/High 51.82 / 77.12
Avg Volume 5.73M
Exchange NYSE
Shares Outstanding 1.67B
Market Cap 124.63B
EPS 0.90
P/E Ratio 26.76
Div & Yield 1.52 (2.00%)

Latest News

Jim Cramer Says Oncology Drug Franchises Helping Both Celgene and Bristol-Myers

Jim Cramer Says Oncology Drug Franchises Helping Both Celgene and Bristol-Myers

Earnings reports from Celgene and Bristol-Myers show the importance of great science for pharma and biotech companies, according to Jim Cramer.

Bristol-Myers (BMY) Stock Slides Despite Q2 Earnings, Revenue Beat

Bristol-Myers (BMY) Stock Slides Despite Q2 Earnings, Revenue Beat

Bristol-Myers (BMY) reported 2016 second-quarter financial results that beat estimates before the market open.

Bristol-Myers Squibb Reports Second Quarter Financial Results

Bristol-Myers Squibb Reports Second Quarter Financial Results

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the second quarter of 2016, which were highlighted by strong sales, key regulatory and clinical milestones in Immuno-Oncology and business development...

3 Stocks Dragging The Health Care Sector Downward

3 Stocks Dragging The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.

Bristol-Myers Squibb Announces New Research Collaboration With Janssen In Immuno-Oncology Focused On Lung Cancer

Bristol-Myers Squibb Announces New Research Collaboration With Janssen In Immuno-Oncology Focused On Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) today announced a new clinical research collaboration with Janssen Biotech, Inc.

Bristol-Myers Squibb Appoints Fouad Namouni, M.D., Oncology Development Head

Bristol-Myers Squibb Appoints Fouad Namouni, M.D., Oncology Development Head

Bristol-Myers Squibb Company (NYSE:BMY) today announced that Fouad Namouni, M.

AbbVie And Bristol-Myers Squibb Announce Oncology Clinical Collaboration To Evaluate The Combination Of Rova-T Plus Opdivo And Opdivo + Yervoy Regimen

AbbVie And Bristol-Myers Squibb Announce Oncology Clinical Collaboration To Evaluate The Combination Of Rova-T Plus Opdivo And Opdivo + Yervoy Regimen

- Collaboration will explore the safety and potential enhanced efficacy of combining checkpoint inhibitors with a cancer stem cell-targeting antibody drug conjugate in SCLC

AbbVie And Bristol-Myers Squibb Announce Oncology Clinical Collaboration To Evaluate The Combination Of Rova-T Plus Opdivo And Opdivo + Yervoy Regimen

AbbVie And Bristol-Myers Squibb Announce Oncology Clinical Collaboration To Evaluate The Combination Of Rova-T Plus Opdivo And Opdivo + Yervoy Regimen

AbbVie (NYSE:ABBV) and Bristol-Myers Squibb Company (NYSE:BMY) today announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie's investigational biomarker-specific antibody...

CHMP Issues Positive Opinion For ORENCIA® (abatacept) In The Treatment Of Highly Active And Progressive Disease In Adult Patients With Rheumatoid Arthritis Not Previously Treated With Methotrexate In The EU

CHMP Issues Positive Opinion For ORENCIA® (abatacept) In The Treatment Of Highly Active And Progressive Disease In Adult Patients With Rheumatoid Arthritis Not Previously Treated With Methotrexate In The EU

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of...

Do the Math! Stocks Are Poised for a Fall

Do the Math! Stocks Are Poised for a Fall

Optimism is warranted over the long haul, but investors probably face a short-term headache. Here are the crucial numbers and events to watch in the week ahead.

Week Ahead: Fed's July Meeting Overshadows Another Busy Earnings Week

Week Ahead: Fed's July Meeting Overshadows Another Busy Earnings Week

The Federal Reserve will steal focus from another onslaught of earnings in the coming week as investors remain wary over the central bank's rate-hike timetable.

Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week

Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week

Cramer is gearing up for the heaviest week of this earnings season, but he's also providing his game plan for helping you be a better investor.

13 Companies to Watch From MIT's Smart 50 List, Including 4 Buys

13 Companies to Watch From MIT's Smart 50 List, Including 4 Buys

MIT's Smart 50 list recognizes companies for their combination of innovative technology and effective management, and it includes 13 pharmaceutical and biotech firms this year.

Bristol-Myers Squibb Announces Availability of FDA-Approved ORENCIA® (abatacept) ClickJect™, a Self-Administered Subcutaneous Autoinjector, for Adults with Moderate to Severe Rheumatoid Arthritis

Bristol-Myers Squibb Announces Availability of FDA-Approved ORENCIA® (abatacept) ClickJect™, a Self-Administered Subcutaneous Autoinjector, for Adults with Moderate to Severe Rheumatoid Arthritis

Bristol-Myers Squibb Company (NYSE:BMY) announced today the commercial launch of the ORENCIA ClickJect TM Autoinjector, a new self-administered autoinjector for adults with moderate to severe rheumatoid arthritis...

'Mad Money' Lightning Round: Take Bristol-Myers Over Juno

'Mad Money' Lightning Round: Take Bristol-Myers Over Juno

Cramer says Abiomed is too expensive while Harman was hurt by the strong dollar.

Jim Cramer's 'Mad Money' Recap: Why Some Stocks Pass Earnings Test and Others Fail

Jim Cramer's 'Mad Money' Recap: Why Some Stocks Pass Earnings Test and Others Fail

Johnson & Johnson was easy, Cramer says, but other stocks were more problematic.

Jim Cramer — J&J Is an Absolutely Terrific Stock

Jim Cramer — J&J Is an Absolutely Terrific Stock

Jim Cramer is impressed by Johnson & Johnson's continual growth.

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.

Cramer: These Stocks Are the Key to the Bull Market

Cramer: These Stocks Are the Key to the Bull Market

Let me give you the unassailable themes.

3 Stocks Dragging In The Drugs Industry

3 Stocks Dragging In The Drugs Industry

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Bristol-Myers Squibb, Radian and SPDR S&P 500 ETF: Doug Kass' Views

Bristol-Myers Squibb, Radian and SPDR S&P 500 ETF: Doug Kass' Views

Doug Kass shares his thoughts on the condition of the global fixed-income markets.

Everything's Fine and Dandy; Jobs Are in the Rearview Mirror: Jim Cramer’s Best Blogs

Everything's Fine and Dandy; Jobs Are in the Rearview Mirror: Jim Cramer’s Best Blogs

Jim Cramer talks about the post-Brexit world, and how it's now all about the earnings as the jobs report recedes in the distance.

Jim Cramer: Lighten Up, the World Is OK for Now

Jim Cramer: Lighten Up, the World Is OK for Now

The world didn't end two weeks ago, Cramer says, so everyone should just calm down and tune out the pundits.

Cramer: All Is OK With the World, and That's Fine for Now

Cramer: All Is OK With the World, and That's Fine for Now

Brexit wasn't the cataclysmic event many pundits wailed about, and while there is still uncertainty, the market is showing its resilience.

Biotech Stock Mailbag: Heron, Exelixis

Biotech Stock Mailbag: Heron, Exelixis

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Goldman Sachs Recommends These 14 Conviction Buy Stocks for the Rest of 2016

Goldman Sachs Recommends These 14 Conviction Buy Stocks for the Rest of 2016

Goldman Sachs expects "rising uncertainty" in the second half of 2016 and suggests that investors stick to stocks within defensive sectors including consumer, health care and telecom services.

Bristol-Myers (BMY) Stock Slides on Swedish Acquisition

Bristol-Myers (BMY) Stock Slides on Swedish Acquisition

Bristol-Myers (BMY) announced today that it has acquired Swedish-based Cormorant Pharmaceuticals for $520 million.